Fate Therapeutics GAAP EPS of -$0.32 beats by $0.07, revenue of $1.63M beats by $0.45M

Stock Information for Fate Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fate Therapeutics Inc.

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.